Clinical trials: Immune Related Disorder
Asthma
Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting
TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G…
- Trial name
- TRIMAXIMIZE (NCT06100042)
- Testing
- BDP/FF/G
- Where
- Italy
- Volunteers
- 233 people
- Sponsor
- Chiesi Italia
AIDS Dementia Complex, HIV Infections
Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy
The purpose of this study is to see if it is safe to give multiple doses of CPI-1189 to HIV-infected, otherwise healthy, males. The study will also look at how CPI-1189 affects the levels of HIV, T cells (cells in the body that…
- Trial name
- NCT00002209
- Testing
- CPI-1189
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Centaur Pharmaceuticals
Sarcoma, Kaposi, HIV Infections
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00002131
- Testing
- Vesnarinone
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Otsuka America Pharmaceutical
Cryptosporidiosis, HIV Infections
The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea
To examine the efficacy of cow's milk immune globulin in the treatment of diarrhea due to chronic intestinal cryptosporidiosis in patients with AIDS.
- Trial name
- NCT00002264
- Testing
- Cryptosporidium Immune Whey Protein Concentrate (Bovine)
- Where
- United States
- Sponsor
- Stolle Milk Biologic International
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
- Trial name
- NCT00002170
- Testing
- Nelfinavir mesylate
- Where
- 5 sites in United States
- Sponsor
- Agouron Pharmaceuticals
HIV Infections
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).
- Trial name
- NCT00002322
- Testing
- Atevirdine mesylate, Zidovudine
- Where
- 12 sites in United States
- Sponsor
- Pharmacia and Upjohn
Multiple Myeloma Bone Disease
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
This study has two portions, a phase I portion and a phase II portion. The purpose of the phase I portion is to assess the maximum-tolerated dose (MTD) and to characterize dose limiting toxicity (DLT) of escalating doses of…
- Trial name
- NCT00741377
- Testing
- BHQ880, Zoledronic acid
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.
- Trial name
- NCT00002238
- Testing
- Interferon beta-1b, Zidovudine
- Where
- 25 sites in United States
- Sponsor
- Bayer
HIV Infections
Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)
Primary: To determine the clinical effect of zidovudine (AZT) compared to placebo in terms of time to progression to AIDS (i.e., occurrence of major opportunistic infections, dementia, and malignancies) or death.
- Trial name
- NCT00002063
- Testing
- Zidovudine
- Where
- 8 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Infections
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
This study will investigate whether the simplified regimen of a once daily fixed dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate [DF]) will be associated with a reduced rate of adverse events, seen…
- Trial name
- NCT00323544
- Testing
- zidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Hematologic Malignancies
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or…
- Trial name
- HPDSC (NCT00596999)
- Testing
- UCB and HPDSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene Corporation
Keratitis, Autoimmunity
A Clinical Study to Evaluate the Safety and Effectiveness of MSCohi-O Lens in the Treatment of Immune-related Ocular Surface Diseases.
Immune-related ocular surface diseases are a kind of non-infectious eye disease pedigree, which is mediated by abnormal immune system function and characterized by ocular surface tissue damage.
- Conditions
- Keratitis, Autoimmunity, Dry Eye Disease (DED)
- Trial name
- NCT07902687
- Testing
- MSCohi-O lens
- Volunteers
- 20 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Immunoglobulin G4 Related Disease
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.
- Trial name
- RILIEF (NCT07190196)
- Testing
- Rilzabrutinib, Glucocorticoid
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction, rhabdomyolysis, myelosuppression, infection, hepatic…
- Trial name
- NCT05137847
- Testing
- Remitoro
- Where
- 3 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Eisai Inc.
Central Neuropathic Pain in Multiple Sclerosis
Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.
- Trial name
- NCT00959218
- Testing
- Dronabinol
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Bionorica Research GmbH
Rhinitis, Allergic, Perennial
Flixonase Safety in Patients With Allergic Rhinitis (AR)
This is an inception cohort study that analyses data from an administrative medical records database. The two inception cohorts are: 1) patients initiated on intranasal FP and 2) patients initiated on another INS (not FP).
- Trial name
- NCT01077609
- Testing
- Intermittent, sub-chronic and chronic Flixonase use, Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Acquired Immunodeficiency Syndrome
Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.
Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R)…
- Trial name
- NCT02583464
- Testing
- Tenofovir disoproxil fumarate and emtricitabine
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorio Elea Phoenix S.A.
Candidiasis, Oral, HIV Infections
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with…
- Trial name
- NCT00002112
- Testing
- Nystatin, Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer